Dialogue with EMA representatives

Peter-Andreas Löschmann, a member of BIO Deutschland’s board, had discussions with representatives of the European Medicines Agency (EMA) on whether delays can be expected in the processing of marketing authorisation applications and in other areas of the agency’s work. EMA has said publicly that there would be no delays, but according to the assessments of various experts, companies should indeed be preparing for delays – due to the fact that not all of EMA’s staff will be making the move to Amsterdam.

Go back